A model-based approach to sample size estimation in recent onset type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 8, 2016, Pages 827-834

  Bundy, Brian N ^a   Krischer, Jeffrey P ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

C peptide; clinical trial; type 1 diabetes

Indexed keywords

ABATACEPT; C PEPTIDE; CANAKINUMAB; DACLIZUMAB; GLUTAMATE DECARBOXYLASE; MYCOPHENOLATE MOFETIL; RITUXIMAB; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; FOLLOW UP; MIDDLE AGED; ONSET AGE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; SAMPLE SIZE; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AREA UNDER CURVE; BIOMARKERS; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; SAMPLE SIZE; YOUNG ADULT;

EID: 84993890052     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2800     Document Type: Article

References (11)

1. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53(1): 250–264.
2. Lachin JM, McGee PL, Greenbaum CJ, et al. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PLoS One 2011; 6(11): e26471.
3. Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012; 61(8): 2066–2073.
4. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010; 33(4): 826–832.
5. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361(22): 2143–2152.
6. Wherrett D, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378(9788): 319–327.
7. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378(9789): 412–419.
8. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013; 381(9881): 1905–1915.
9. Snedecor GW, Cochran WG. Statistical Methods (8th edn). Iowa State UP: Ames, IA, 1989.
10. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965; 52(3/4): 591–611.
11. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980; 48(4): 817–838.